John Schmid
John Schmid has over 30 years of experience in financial and executive management in the biotechnology industry and has raised over $900 million in private and public equity and debt financings. Mr. Schmid is currently an independent board member of AnaptysBio Inc., Poseida Therapeutics Inc., Helix Acquisition Corp. II, Design Therapeutics, Inc., and Speak, Inc. Mr. Schmid has also served as Chairman of the Board of Directors of Blacksmith Medicines, Inc. (formerly Forge Therapeutics).
Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals, which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex Pharmaceuticals, Mr. Schmid cofounded Trius Therapeutics in 2004; there, he served as CFO through its initial public offering until its sale to Cubist Pharmaceuticals in 2013 for over $700 million.
Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals, which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex Pharmaceuticals, Mr. Schmid cofounded Trius Therapeutics in 2004; there, he served as CFO through its initial public offering until its sale to Cubist Pharmaceuticals in 2013 for over $700 million.
Committee Roles:
Chair of the Audit Committee
Member of the Compensation Committee